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β-adrenoceptors in patients with primary VA, conduction disturbances and idiopathic cardiomyopathy suggests a common or similar abnormal immunoregulatory process. 18 Moreover, functionally active aβ1AA could increase β-adrenoceptor signaling, inducing apoptosis of cardiomyocytes. 24 The aim of our study was to determine the prevalence of autoantibodies against β-adrenoceptors in patients with IA and to evaluate a correlation with histological findings whenever EMB was clinically required according to current guidelines. 25 
Methods
We included 112 subjects, divided into 4 groups, the demographic, clinical, histological and immunological data of which are summarized in Tables 1-4 Table 2 )], all without evidence of structural heart disease, according to clinical history, physical examination and instrumental evaluation including 24-h ECG Holter monitoring, exercise ECG testing and echocardiography. Biochemical laboratory data were normal. 22 SVA and 34 VA patients were symptomatic for palpitation ( Tables 1,2 ). All patients were untreated when enrolled. Group 2: 14 patients (mean age 39.4±18.8) also with arrhythmias, but excluded from group 1 because of clinical suspicion of myocarditis or cardiomyopathy on the basis of minor cardiac abnormalities, as evidenced by ECG and/or echocardiography ( Table 3) . Group 3: 12 patients (mean age 36.6±12.7), all symptomatic, with overt cardiomyopathy and/or myocarditis as demonstrated by echocardiography and EMB, with and without arrhythmias ( Table 3) . Group 4: 19 healthy subjects without any history or evidence of arrhythmias (mean age 34.1±12.6) were included as a control group (Table 4) .
Coronary artery disease (CAD), severe hypertension, alcoholism, valvular heart disease, insulin-dependent diabetes mellitus, severe infection, cor pulmonale, mediastinal irradiation, and post-chemotherapy cardiac dysfunction were exclusion criteria for groups 1 and 2. None of the patients had been treated with β-blockers for at least 5 weeks before blood sampling.
The study was approved by the local Ethics Committee and performed in accordance with the 1964 Declaration of Helsinki. All patients gave their informed consent prior to inclusion in the study.
Immunologic Studies
Patients' sera were tested for the presence of aβ1AA-and anti-β2-adrenoceptor autoantibodies (aβ2AA) using the enzyme immunoassay method described by Magnusson et al. 26 All studies were performed on serum samples stored at −25°C.
Peptides Two peptides synthesized using the solid phase method 18 were used to assay aβ1AA and aβ2AA in the patients' sera. The β1 peptide corresponds to the postulated second extracellular loop amino acid sequence 183-208 of the human β1-adrenergic receptor (HWWRAESDEARRCYNDPKCCD-FVTNR). The β2 peptide corresponds to the postulated second TNQ) . Both peptides have a cysteine group as a carboxy terminus. As a positive control, rabbit monospecific affinity-purified antibodies against the β1 peptide were used. 26 Enzyme Immunoassay Fifty-μl of 0.1 mol/L Na2CO3 solution supplemented with 1% (vol/vol) β-mercaptoethanol containing 50 μg/ml of peptide was absorbed for 1 h at room temperature on NUNC microtiter plates. The wells were then saturated with phosphate-buffered saline (10 mmol/L phosphate, 140 mmol/L NaCl, pH 7.4) supplemented with 3% (W/vol) of skimmed milk, 0.1% (vol/vol) of Tween 20, and 0.01% (W/vol) of merthiolate (PMT). Fifty μl of dilutions of the sera from 1:20 to 1:160 in PMT were allowed to react with the peptides overnight at 4°C. After washing the wells 3 times with PMT, 0.05 ml of an affinity-purified biotinylated rabbit anti-human IgG antibody solution diluted 1:1,000 in PMT was allowed to react for 1 h at room temperature. After 3 more washing, the bound biotinylated antibody was then detected by incubation of the plates for 1 h at room temperature with 0.05 ml/well of a 1-μg/ml solution of streptavidin peroxidase (Sigma Chemical, St Louis, MO, USA) in PMT followed by 
. After 30 min, the optical densities were read at 405 nm in an ELISA reader. Positivity was defined as 2.5-fold of the background optical density. 26 Functional Tests of the Anti-β-Receptor Antibodies Sera of 14 group 1 patients (7 with VA, 7 with SVA) found positive for aβ1AA (2 of them positive also for anti-β2 antibodies) were functionally tested. A detailed description has been given previously. 19,27 Briefly, the IgG fraction was isolated by ammonium sulfate precipitation and tested for functional (chronotropic) effects on the rate of beating of cultured neonatal rat cardiomyocytes. Single cells were dissociated from the minced ventricles with a 0.2% solution of trypsin and were cultured at 37°C for 4 days as monolayers (90,000 cells/cm 2 ). For the experiment, the cells were sensitized for β-adrenoceptor response by the addition of 10 mmol/L of 15-hydroxyeicositetraenic acid and incubated for 2 h as monolayers on a slowly moving rocker apparatus. The number of beats of a selected isolated myocardial cell (or a cluster of synchronous contracting cells) was visually counted for 15 s with an inverted Zeiss microscope. The procedure was repeated twice in different cultures to yield results representing a total of 10 cells or cell clusters, before and 60 min after preincubation with the IgG at dilutions of 1:10 to 1:100. The counting was repeated after adding the selective β1-adrenergic blocking agent bisoprolol (1 μmol/L). All functional tests were performed in a blinded manner.
Invasive Studies
All group 3 patients underwent coronary angiography, ventriculography and EMB, as requested by clinical practice and current guidelines. 25 Patients belonging to groups 1 and 2 underwent EMB only when an underlying myocarditis or other clinically silent cardiomyopathy was suspected, because of the coexistence of refractoriness to antiarrhythmic therapy (which was defined as lack of responsiveness to flecainide, propafenon and sotalol tested in sequence under 24-h ECG Holter monitoring), of cardiac abnormality on magnetic resonance imaging (MRI) suggesting a myocarditis or other cardiomyopathy 9 and of anti-β-adrenoceptors autoimmunity.
Because the EMB was not guided by 3-dimensional electroanatomical mapping, which facilitates correctly aiming at Tables 1,2 . Autoimmunity Against β-Adrenoceptors and Arrhythmias the abnormal/arrhythmogenic substrates, 28 at least 3 samples were taken from 1 ventricular chamber (or with biventricular approach), because inflammatory or cardiomyopathic lesions are often present in some but not all samples and multiple samples are necessary for an accurate histological diagnosis. The samples of myocardial tissue were treated as previously described. 4,6,7 The diagnosis of myocarditis was established by the presence of inflammatory infiltrates (mostly lymphocytes, with some plasma cells, mast cells, histiocytes) in the myocardium, with necrosis or degeneration of the myocytes not typical of ischemic damage. Focal, scant or diffuse fibrosis suggested an acute, healing or healed inflammation. Immunohistochemistry was carried out for CD8, 20, 43, 45Ro and 68. The diagnosis of myocarditis is supported by evidence of CD45Ro-positive inflammatory infiltrates (=14/2 mm), associated with focal necrosis of the adjacent myocytes. 9 Polymerase chain reaction (PCR) was performed on the material of paraffin blocks of 11 (group 1) biopsied patients positive for aβ1AA. An extensive panel was used, including the following viral genomes: EV, EBV, HCV, AV, PVB19, INF A/ B, HSV1/2, HHV6 and HHV8.
The diagnosis of cardiomyopathy was made in the presence of hypertrophy with attenuation and vacuolar degeneration of myocardial fibers, occasionally associated with mild interstitial and perivascular fibrosis. Histological findings suggestive of arrhythmogenic right ventricular cardiomyopathy were severe fibrofatty infiltration in right ventricular specimens, occupying >50% of the morphometrically assessed areas in 2 of 3 right ventricular samples and associated with cardiomyocyte atrophy. 29 
Statistical Analysis
The significance between different groups was assessed by chi-square analysis using contingency tables calculated by the Statview 4.0 program for Macintosh. Significance was assessed at P<0.05.
The increase in beating frequency of cultured rat cardiomyocytes compared with the corresponding control period before the addition of IgG was analyzed using a paired Student's t-test. Results are expressed as mean value ± standard deviation. A probability level of P<0.05 was chosen as the least significant difference.
Results

Immunologic Studies
Anti-β1-and β2-Adrenoceptor Autoantibodies (Figure 1 ) Group 1: 38/67 patients (56.7%) were positive for aβ1AA. In particular, 11/25 (44%) SVA patients (group 1a, Table 1 ), 1 with focal atrial tachycardia, 2 with atrial flutter, 8 with paroxysmal atrial fibrillation, had a positive titer for aβ1AA; 1 (4%) was also positive for aβ2AA; 3/25 were positive for aβ2AA only. 10/11 patients with SVA (90%) and positive for aβ1AA had paroxysmal atrial fibrillation or flutter. 27/42 (64.2%) VA patients (group 1b, Table 2 ), 18 of them in Lown class 4 (66.6%), had a positive titer for aβ1AA. 2 patients were also positive for aβ2AA. 1/42 patients (2.3%) had a positive titer for aβ2AA only. Atrial and ventricular diameters/volumes, EF and myocardial thickness were normal at echocardiography in all group 1 patients. Group 2: 5/14 patients (35.7%) were positive for aβ1AA, 1/8 with VA (12.5%) and 4/6 with SVA (66%). None was positive for aβ2AA ( Table 3) . Group 3: 6/12 patients (50%) were positive for aβ1AA. 1, with a history of lupus myocarditis, was also positive for aβ2AA ( Table 3) . Group 4: Only 3/19 (15.7%) subjects were positive for aβ1AA ( Table 4 ).
The differences in aβ1AA prevalence between the controls (group 4) and group 1 (P<0.01), group 1a (P<0.05), group 1b (P<0.001), group 3 (P<0.05) and group 1 plus group 2 plus group 3 (P<0.01) patients were statistically significant. No significant difference in aβ1AA prevalence was found among the first 3 groups. The prevalence of aβAA analyzed separately in the 2 group 1 subgroups is shown in Table 5 .
Functional Test of Anti-β-Adrenoceptor Antibodies All patients sera were positive for aβ1AA. As shown in Figure 2 , the IgG (at dilution 1:50) from all patients caused a positive chronotropic effect of the isolated rat cardiomyocytes ranging between 21.3 and 36.8 beats/min (27.4±6.1 beats/min), significantly higher than the changes in beating rate induced by the sera of anti-β1-antibodies negative controls (0.7±1.9 beats/min) (P<0.0001). Sera of the 12 healthy controls ( Figure 2C ) did not induce a significant chronotropic effect, suggesting that positivity for aβ1AA was related to 'naturally occurring antibodies' that may recognize the synthetic peptides but not the specific functional epitopes. 18,26
Invasive Study 29 patients (11 in group 1, 6 in group 2, 12 in group 3) had abnormal findings on EMB. Group 1: no patient had significant CAD or left ventricular wall motion abnormalities. Although EMB was not guided by 3D electroanatomical imaging, the high number of positive findings can be explained by the fact that often a biventricular approach was used or at least 3 samples were taken from the ventricular chamber. Histological abnormalities were found in all 11 biopsied group 1 patients, with a high prevalence (9/11, 81%) of myocarditis. 7/8 (87.5%) VA patients with abnormal histology were positive for aβ1AA, being 6 of them affected by different stages of myocarditis. Inflammatory or cardiomyopathic lesions were often present in some but not all samples. Among the 11 patients with paroxysmal SVA and aβ1AA seropositivity, 3, who underwent EMB, had a myocarditis. Group 2: 5/6 patients (83%) who underwent EMB had a healing myocarditis. Three (50%) were also positive for aβ1AA. Group 3: all patients had abnormal histology, 11/12 (91.6%) for acute or healing myocarditis and 1 for DCM. Six (50%) had a positive titer for aβ1AA. The diagnosis of myocarditis was supported by immunohistochemistry, which evidenced CD45Ro-positive inflammatory infiltrates (=14/2 mm), associated with focal necrosis of the adjacent myocytes. Retrospective PCR on the bioptic material of paraffin block of 11 aβ1AA positive patients failed to identify viral genomes regarding EV, EBV, HCV, AV, PVB19, INF A/B, HSV1/2, HHV6, HHV8. A representative case of positive EMB in a patient with idiopathic ventricular tachycardia (VT) and aβ1AA is shown in Figure 3 .
Discussion
Circulating aβ1AA are frequently found in patients with idiopathic DCM, in whom autoimmunity represents one of the most relevant pathogenetic mechanisms. 32 and has been found to be associated with a higher incidence of VT and sudden death with respect to negative subjects. 20 A high prevalence of functionally active aβ1AA was previously reported in patients with primary VA and conduction disturbances in the absence of other structural cardiac abnormality. 18 In this study, using the same method, 26 we have found an overall 56.7% prevalence of aβ1AA in patients with IA (Figure 1) , somehow lower than that reported by others. 17, 20 The prevalence of aβ1AA in the sera of patients with primary VA and in those with idiopathic SVA was significantly higher than that observed in the sera of normal subjects (P<0.001 and P<0.05, respectively) and was also higher than that found in patients with non-arrhythmogenic idiopathic DCM. 15,18, 31 In our subgroup of aβ1AA-positive patients with IA who underwent EMB, inflammatory infiltration or histological evidence of DCM was frequently found ( Table 1) , supporting the hypothesis that autoimmunity could be the common pathogenetic mechanism for myocarditis, arrhythmias and evolution to DCM. 12,14,17,18 It remains to be clarified whether autoimmunity against a functional epitope of the β1-adrenoceptor in patients with IA is only a marker of an arrhythmogenic concealed cardiomyopathy or is also a pathogenic factor for the occurrence of arrhythmias. 16-18,20,21 Some evidence of aβ1AA arrhythmogenicity has been experimentally demonstrated. In isolated cardiomyocytes, aβ1AA induce an acute increase in the L-type calcium current and prolongation of the action potential duration. 35 Rabbits immunized with a synthetic peptide corresponding to the second extracellular loop of the β1-adrenoceptor showed prolongation of the QT interval and more frequently developed sustained VT episodes with respect to controls. The action potential recorded from their right ventricular papillary muscles were abnormally prolonged, with a decrease in specific potassium currents densities and occurrence of early afterdepolarization. 30 Beta-receptor downregulation because of the agonistic effects of aβ1AA 14,15,17,19,32,33 could be proarrhythmic by inducing structural changes in the proteins controlling electrophysiological functions, such as ion channels and pumps/carriers. 35 In all of our 14 patients (Figure 2) , functional testing of their purified aβ1AA confirmed a chronotropic effect caused by β1-adrenoceptors agonism. Such a potentially arrhythmogenic effect was neutralized by the selective β1-blocker, bisoprolol, in only 57% of the patients. Thus, other functionally active autoantibodies (different from aβ1AA) could be responsible of stimulating action on β-adrenoceptors or inhibition of muscarinic receptors. 17 In 1 group 1b patient (no. 42 in Table 2 ), with 'idiopathic' unsustained VT, an apparently normal heart and abnormal EMB, the gamma-globulin fraction not absorbed on the peptide column (flow through) was still able to induce a positive chronotropic effect, which was blocked with neither β-nor α-blockers. Such behavior, not observed in previous studies, 18,19 might confirm the presence of other arrhythmogenic autoantibodies, with molecular targets different from β1-adrenoceptors. Interestingly in this patient the VT was resistant to β-blocker administration, but totally abolished by flecainide.
All sera were tested also for the presence of aβ2AA, because human cardiac β2-adrenoceptors are distributed in both atrial and ventricular tissue and might play a significant role in the control of both inotropic and chronotropic responses. 17, 35 In our group 1 patients, the aβ2AA positivity ranged between 7.1% (group 1b) and 16% (group 1a) ( Table 1 ). This suggests that autoimmunity against cardiac β2-adrenoceptors was somehow prevented in most of our cases, as previously observed in patients with idiopathic DCM, in whom the β2-adrenoceptor function seems to be maintained. 35 However, because functionally active aβ2AA have been found in patients with primary VA, 18 the role of autoimmunity against cardiac β2-adrenoceptors deserves further investigation.
Study Limitations
Although the novel finding of this study is that a clinicalpathological correlation was attempted, an obvious limitation is that EMB was performed in only 11/67 cases with IA, when refractory to antiarrhythmic therapy and/or with MRI abnormality suggestive of myocarditis or DCM. To unequivocally define the correlation between the prevalence of anti-β-adrenoceptors autoantibodies positivity and that of abnormal histological findings, EMB should have been performed in all patients. On the other hand, extensive use of an invasive procedure was ethically unjustified and avoided according to current guidelines, 25 as the majority of patients were in optimal clinical condition and/or respondent to antiarrhythmic treatment. Our choice, although a limitation of the study protocol, does not detract from the validity of our results in showing a high prevalence of aβ1AA in patients with IA and histological evidence inflammatory pathology or DCM.
A second limitation is that functional testing of seropositive patients was limited to 14 patients, most of them (12/14) with aβ1AA only, and only the effect of bisoprolol was systematically tested in all of them. In order to understand whether or not anti-β-adrenoceptor autoantibodies play a pathogenic role in the electrogenesis of the arrhythmias observed in our patients, more systematic studies would be needed to test patients' sera also for the presence and functional effects of other types of antibodies against autonomic receptors, with a more accurate definition of their pharmacological properties, possibly on isolated human myocardiocytes. 17 The 15.7% positivity for aβ1AA found in our healthy subjects does not affect the meaning of our findings. In fact, it is consistent with previous reports 18, 26 and was already explained by the existence of natural antibodies without functional effect. Interestingly, the IgG of our aβ1AA-positive healthy subjects did not induce a positive chronotropic response in isolated rat myocytes (Figure 2) . Furthermore, all 3 were young healthy subjects who did not develop any arrhythmia or cardiomyopathy during clinical follow-up.
Conclusions
This study confirms that the second extracellular loop of the β1-adrenoceptor is the molecular target of specific autoantibodies in patients with primary arrhythmias, as well as in patients with DCM. The higher incidence of functionally active aβ1AA, as compared to healthy controls, is in agreement with previous work 17,18,20,26 and confirms the hypothesis that autoimmunity might play an arrhythmogenic role in patients with arrhythmias of unknown origin, by sustained stimulation of β1-adrenoceptor, although such a proarrhythmic effect might be dependent on underlying concealed cardiac pathology as evidenced by EMB.
We believe that functionally active autoimmunity against β-adrenoceptors is most probably a post-myocarditis event, which can induce arrhythmias in an early and clinically silent phase of the disease, much in advance of the occurrence of the structural remodeling that leads to DCM. 10,11,20,23 Therefore, we suggest that screening for autoimmunity against β-adrenoceptors could be an additional tool to confirm a clinical suspicion of underlying concealed persistent inflammatory cardiomyopathy in subjects with IA that are resistant to antiarrhythmic therapy, and to validate further invasive investigation, including EMB, in otherwise apparently normal subjects. In fact, the association of aβ1AA positivity with abnormal histological findings on EMB, observed in 100% of the investigated patients with SVA and 87.5% of patients with VA, suggests a 90% probability that patients with IA, if positive in immunological tests, are affected by a 'concealed' cardiac pathology and deserve further invasive investigation.
